Myriad Genetics prices upsized 6.47M-share offering at $17.00 for ~$110M gross

MYRIAD GENETICS INC

Offering of 6,470,588 shares upsized; priced at $17.00/share; expected gross proceeds ~$110M.
Underwriters granted 30-day option for up to 970,588 additional shares at same price.
Net proceeds: ~$40M to repay asset-based revolving credit facility; ~$57.5M to settle securities class action (In re Myriad Genetics).
Remainder for working capital and general corporate purposes; closing expected Nov 13, 2023.
Goldman Sachs, Morgan Stanley, and Wells Fargo acting as joint book-running managers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.